# US 2010/0167290 A1 · Molecule attachment to nanoparticles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167290 A1
- Document ID: US20100167290A1
- Status: Published application
- Kind: A1
- Application number: 12/527,623
- Filed: 2008-02-27
- Published: 2010-07-01
- Earliest claimed: 2007-02-27
- Inventors: Robert Elghanian; Chad A. Mirkin
- Web page: https://patentgrep.com/patent/US20100167290A1

## CPC

- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- A61P 35/00: Antineoplastic agents
- G01N 33/5432: {Liposomes or microcapsules}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are molecule-modified nanoparticles and methods of making and using the same. More specifically, disclosed herein are molecule-modified nanoparticles wherein the molecule is attached to the surface of the nanoparticle via an oligonucleotide. Also disclosed are methods of preparing nanoparticles having oligonucleotides and molecules (e.g., biomolecules, such as proteins, peptides, antibodies, lipids, and/or carbohydrates) attached to the nanoparticle surface, wherein the oligonucleotide and molecule are covalently attached. Further disclosed are methods of detecting an analyte of interest using these disclosed molecule-modified nanoparticles.

## Claims

### Claim 1

A molecule-modified nanoparticle comprising a molecule covalently attached to an oligonucleotide, the oligonucleotide further covalently attached to a nanoparticle.

### Claim 2 (depends on 1)

The molecule-modified nanoparticle of claim 1, wherein the oligonucleotide has a first end and a second end, and the molecule is attached at the first end and the nanoparticle is attached at the second end.

### Claim 3 (depends on 1)

The molecule-modified nanoparticle of claim 1, wherein the molecule is a biomolecule.

### Claim 4 (depends on 3)

The molecule-modified nanoparticle of claim 3, wherein the biomolecule is selected from the group consisting of a protein, a peptide, an antibody, a lipid, a carbohydrate, and combinations thereof.

### Claim 5 (depends on 2)

The molecule-modified nanoparticle of claim 2, wherein the biomolecule is an antibody.

### Claim 6 (depends on 1)

The molecule-modified nanoparticle of claim 1, wherein the nanoparticle has a diameter of about 10 nm to about 100 nm.

### Claim 7 (depends on 1)

The molecule-modified nanoparticle of claim 1, wherein the nanoparticle is metallic.

### Claim 8 (depends on 7)

The molecule-modified nanoparticle of claim 7, wherein the metal is selected from the group consisting of gold, silver, platinum, aluminum, palladium, copper, cobalt, indium, nickel, and mixtures thereof.

### Claim 9 (depends on 1)

The molecule-modified nanoparticle of claim 1, wherein the nanoparticle comprises gold.

### Claim 10 (depends on 9)

The molecule-modified nanoparticle of claim 9, wherein the oligonucleotide is attached to the nanoparticle via a functional group moiety, said functional group moiety comprising a sulfur atom.

### Claim 11 (depends on 10)

The molecule-modified nanoparticle of claim 10, wherein the oligonucleotide was prepared using a dithiol phosphoramidite (DTPA).

### Claim 12 (depends on 1)

The molecule-modified nanoparticle of claim 1, wherein the oligonucleotide is 20 nucleobases to 150 nucleobases in length.

### Claim 13

A method of preparing a molecule-modified nanoparticle comprising
a) contacting a nanoparticle with an oligonucleotide having a functional group moiety toward a first end and a leaving group toward a second end to form an oligonucleotide-modified nanoparticle such that the oligonucleotide is attached to a surface of the nanoparticle via the functional group moiety; and
b) contacting the oligonucleotide-modified nanoparticle of (a) with a molecule having a nucleophile under conditions sufficient to permit displacement of the leaving group on the oligonucleotide by the nucleophile of the molecule to form the molecule-modified nanoparticle.

### Claim 14 (depends on 13)

The method of claim 13, wherein the molecule is a biomolecule.

### Claim 15 (depends on 14)

The method of claim 14, wherein the biomolecule is selected from the group consisting of a protein, a peptide, an antibody, a lipid, a carbohydrate, and combinations thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the biomolecule is an antibody.

### Claim 17 (depends on 13)

The method of claim 13, wherein the nucleophile is a hydroxyl, amine, or thiol.

### Claim 18 (depends on 13)

The method of claim 13, wherein the leaving group is selected from the group consisting of tosyl, mesyl, trityl, substituted trityl, nitrophenyl, chlorophenyl, fluorenylmethoxy carbonyl, and succinimidyl.

### Claim 19 (depends on 13)

The method of claim 13, wherein the nanoparticle is metallic.

### Claim 20 (depends on 19)

The method of claim 19, wherein the metal is selected from the group consisting of gold, silver, platinum, aluminum, palladium, copper, cobalt, indium, nickel, and mixtures thereof.

### Claim 21 (depends on 19)

The method of claim 19, wherein the nanoparticle comprises gold.

### Claim 22 (depends on 13)

The method of claim 13, wherein the nanoparticle has a diameter of about 10 nm to about 100 nm.

### Claim 23 (depends on 13)

The method of claim 13, wherein the oligonucleotide is 20 nucleobases to 150 nucleobases in length.

### Claim 24 (depends on 1)

A method of detecting an analyte in a sample comprising
a) contacting the sample with a molecule-modified nanoparticle of claim 1 under conditions to permit binding of the analyte to the molecule, and
b) detecting the analyte bound to the molecule-modified nanoparticle, wherein the binding of the analyte to the molecule-modified nanoparticle produces a detection event.

### Claim 25 (depends on 24)

The method of claim 24, wherein the molecule is a biomolecule.

### Claim 26 (depends on 25)

The method of claim 25, wherein the biomolecule is selected from the group consisting of a protein, a peptide, an antibody, a lipid, a carbohydrate, and combinations thereof.

### Claim 27 (depends on 24)

The method of claim 24, wherein the oligonucleotide is at least partially complementary to a probe oligonucleotide and the oligonucleotide and probe oligonucleotide are hybridized.

### Claim 28 (depends on 27)

The method of claim 27, wherein the detection event comprises melting the hybridized oligonucleotide and probe oligonucleotide and detecting the probe oligonucleotide.

### Claim 29 (depends on 24)

The method of claim 24, wherein the detection is sensitive to detect the analyte at a concentration down to about 300 fM.
